+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hypertrophy Medication Market - Global Forecast 2026-2032- Product Image
Benign Prostatic Hypertrophy Medication Market - Global Forecast 2026-2032- Product Image
Sale

Benign Prostatic Hypertrophy Medication Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6080410
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benign Prostatic Hypertrophy Medication Market is projected to reach USD 9.16 Billion in 2026. It is expected to continue growing at a CAGR of 6.28%, reaching USD 13.15 Billion by 2032.

Benign Prostatic Hypertrophy Medication: Executive Overview

Benign prostatic hypertrophy (BPH), commonly termed benign prostatic hyperplasia, is a noncancerous enlargement of the prostate that can obstruct urine flow and produce lower urinary tract symptoms. Medication remains an important management option, particularly for patients with mild to moderate symptoms, enlarged prostates, or elevated risk of progression. Treatment selection depends on symptom severity, prostate characteristics, comorbidities, adverse-effect tolerance, and patient preferences. Common pharmacological approaches include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, and combination regimens, while treatment pathways also include monitoring, lifestyle measures, minimally invasive procedures, and surgery.

Treatment Pathways Are Shifting Toward Personalized, Longitudinal Care

The treatment landscape is moving beyond symptom suppression toward individualized, longitudinal management. Clinicians increasingly distinguish between rapid symptom relief and reduction of disease progression risk, using prostate volume, prostate-specific antigen levels, urinary flow, residual urine, symptom scores, and treatment response to guide decisions. Combination therapy can address complementary mechanisms but may increase complexity and adverse-effect concerns. Shared decision-making is therefore central, especially when sexual dysfunction, dizziness, blood-pressure effects, or treatment persistence influence adherence. Earlier identification of worsening symptoms and clearer referral pathways also support timely evaluation for urinary retention, recurrent infection, hematuria, renal impairment, or suspected malignancy.

Artificial Intelligence Can Strengthen Diagnosis, Adherence, and Care Coordination

Artificial intelligence can support BPH care by organizing symptom questionnaires, identifying patients at risk of progression, assisting interpretation of uroflowmetry and imaging, and improving clinical-trial recruitment. Predictive tools may help clinicians compare expected benefits and adverse-effect risks across medication strategies when integrated with validated clinical data. Digital reminders and remote symptom tracking can reinforce adherence and identify treatment failure earlier. However, AI should remain an assistive capability: outputs require clinical validation, transparent data governance, protection of sensitive health information, and safeguards against demographic or socioeconomic bias. Evidence should demonstrate improved patient outcomes rather than relying solely on technical accuracy.

Regional Insights: Access, Diagnosis, and Treatment Capacity Vary Widely

North America generally benefits from broad access to primary care, urology services, prescription medicines, and minimally invasive treatment, although affordability, insurance design, and specialist availability remain important considerations. Europe combines established clinical guidance with diverse reimbursement systems and uneven access across countries. Asia-Pacific includes highly developed healthcare systems alongside rapidly expanding urban and specialist capacity, with diagnosis often shaped by aging populations and differences in health-seeking behavior. Latin America faces variation in public-sector resources, medicine access, and specialist coverage, making primary-care protocols and generic availability important. The Middle East is characterized by concentrated specialist capacity in major urban centers and differing reimbursement arrangements. Africa has substantial unmet need linked to limited diagnostic infrastructure, specialist shortages, delayed presentation, and medicine affordability; scalable primary-care screening and referral systems are particularly relevant.

Group Insights: Policy Alignment and Health-System Structure Shape Uptake

ASEAN members face diverse healthcare financing, regulatory, and specialist-capacity conditions, creating a need for adaptable treatment protocols and dependable medicine supply. BRICS countries combine large patient populations with marked differences in public coverage, domestic manufacturing, procurement, and urban-rural access. The European Union benefits from shared scientific and regulatory cooperation while retaining national differences in reimbursement and service delivery. G7 systems generally have mature diagnostic and pharmacological capabilities, but must address aging populations, polypharmacy, treatment adherence, and cost-effectiveness. GCC countries often have comparatively concentrated specialist services and strong urban infrastructure, while workforce distribution and reliance on imported medicines can affect continuity. NATO members span varied health systems, so interoperability of clinical guidance, medicine supply resilience, and preparedness for cross-border health pressures remain relevant.

Country Insights: National Contexts Create Different Priorities

Australia and Canada must balance extensive geographic coverage with timely access to primary care and urology services. Brazil and Mexico face regional disparities in public provision, diagnosis, and medicine availability. China and India have large and aging populations, with priorities including standardized diagnosis, tiered referral, and broader access beyond major cities. Japan and South Korea have advanced healthcare infrastructures and aging demographics, making treatment persistence, polypharmacy, and quality-of-life outcomes important. France, Germany, Italy, and Spain operate within established European systems but differ in reimbursement, prescribing practice, and waiting times. The United Kingdom emphasizes guideline-based care and primary-care management while managing referral capacity. The United States offers extensive therapeutic and procedural options, but insurance coverage, out-of-pocket costs, and fragmented care can influence treatment choice. Russia faces distinct challenges related to regional access, supply continuity, and specialist availability. Across all countries, clinicians must differentiate BPH symptoms from infection, neurogenic bladder, urethral obstruction, and prostate cancer.

Prioritize Evidence-Based Access, Adherence, and Integrated Care

Industry leaders should support therapies with clinically meaningful evidence on symptom improvement, urinary flow, progression risk, quality of life, persistence, and safety in older adults with comorbidities. Patient-centric packaging, plain-language education, adherence support, and shared-decision tools can improve appropriate use without encouraging unnecessary treatment. Organizations should work with health systems to strengthen primary-care algorithms, referral criteria, pharmacovigilance, and continuity of supply, while tailoring implementation to local reimbursement and regulatory requirements. Digital and AI-enabled services should be introduced only with validated endpoints, human oversight, cybersecurity controls, and transparent performance monitoring. Access strategies should include responsible generic competition, equitable distribution, and partnerships that improve diagnostic and treatment capacity in underserved areas.

Research Methodology: Evidence-Centered Market Assessment

This executive summary uses a structured review framework focused on the clinical and health-system dimensions of medication for benign prostatic hypertrophy. The assessment considers established disease-management pathways, recognized treatment classes, patient-selection factors, safety and adherence issues, diagnostic requirements, regulatory and reimbursement context, and differences in healthcare access across the specified regions, groups, and countries. Findings are framed qualitatively and avoid market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims. Interpretation should be updated as clinical guidelines, comparative evidence, safety information, and national access policies change.

The Opportunity Is Better Coordinated, Patient-Centered BPH Management

Medication for benign prostatic hypertrophy remains most effective when embedded in a broader pathway that combines accurate assessment, individualized prescribing, monitoring, and timely escalation. The central priorities are improving diagnosis, preserving treatment adherence, managing adverse effects, and reducing inequities in access to primary and specialist care. Regional and national differences require flexible implementation rather than a single global model. Leaders that pair robust clinical evidence with responsible digital innovation, reliable supply, and health-system collaboration can help deliver safer, more continuous, and more patient-centered care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Benign Prostatic Hypertrophy Medication Market, by Product Type
7.1. Introduction
7.2. 5-Alpha Reductase Inhibitors
7.2.1. Dutasteride
7.2.2. Finasteride
7.3. Alpha Blockers
7.3.1. Alfuzosin
7.3.2. Doxazosin
7.3.3. Tamsulosin
7.3.4. Terazosin
7.4. Combination Therapies
7.4.1. Dutasteride Tamsulosin
7.4.2. Finasteride Tamsulosin
8. Benign Prostatic Hypertrophy Medication Market, by Drug Type
8.1. Introduction
8.2. Branded
8.3. Generic
9. Benign Prostatic Hypertrophy Medication Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Benign Prostatic Hypertrophy Medication Market, by Age Group
10.1. Introduction
10.2. 45 to 64
10.3. Above 65
10.4. Below 45
11. Benign Prostatic Hypertrophy Medication Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Benign Prostatic Hypertrophy Medication Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Benign Prostatic Hypertrophy Medication Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Astellas Pharma Inc.
15.3. Bayer AG
15.4. Cipla Limited
15.5. Dr. Reddy’s Laboratories Ltd.
15.6. Eli Lilly and Company
15.7. Ferring Pharmaceuticals
15.8. GlaxoSmithKline plc
15.9. Lupin Limited
15.10. Merck & Co., Inc.
15.11. Novartis AG
15.12. Pfizer Inc.
15.13. Sanofi S.A.
15.14. Sun Pharmaceutical Industries Ltd.
15.15. Teva Pharmaceutical Industries Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Benign Prostatic Hypertrophy Medication Market, Years Considered for the Study
FIGURE 2. Global Benign Prostatic Hypertrophy Medication Market, Research Design
FIGURE 3. Global Benign Prostatic Hypertrophy Medication Market, Research Framework
FIGURE 4. Global Benign Prostatic Hypertrophy Medication Market, Data Triangulation
FIGURE 5. Global Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2025 vs 2032 (%)
FIGURE 9. Global Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Benign Prostatic Hypertrophy Medication Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Benign Prostatic Hypertrophy Medication Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Benign Prostatic Hypertrophy Medication Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Benign Prostatic Hypertrophy Medication Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Benign Prostatic Hypertrophy Medication Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Benign Prostatic Hypertrophy Medication Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Benign Prostatic Hypertrophy Medication Market Segmentation & Coverage
TABLE 2. Global Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 3. Global Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global 5-Alpha Reductase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global 5-Alpha Reductase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global 5-Alpha Reductase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Dutasteride Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Dutasteride Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Dutasteride Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Finasteride Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Finasteride Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Finasteride Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Alpha Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Alpha Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Alpha Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Alfuzosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Alfuzosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Alfuzosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Doxazosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Doxazosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Doxazosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Terazosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Terazosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Terazosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Combination Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Combination Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Combination Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Dutasteride Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Dutasteride Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Dutasteride Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Finasteride Tamsulosin Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Finasteride Tamsulosin Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Finasteride Tamsulosin Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 38. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Generic Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Generic Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Generic Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 45. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 55. Global 45 to 64 Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global 45 to 64 Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global 45 to 64 Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Above 65 Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Above 65 Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Above 65 Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Below 45 Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Below 45 Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Below 45 Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 73. North America Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. North America Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. North America Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 76. North America Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 77. North America Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 78. North America Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 79. North America Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. North America Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 81. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 83. Latin America Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 84. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 85. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 86. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 87. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. Latin America Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 89. Europe Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Europe Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Europe Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 92. Europe Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 93. Europe Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 94. Europe Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 95. Europe Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 96. Europe Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 97. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 99. Middle East Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 100. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 101. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 102. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 103. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 104. Middle East Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 105. Africa Benign Prostatic Hypertrophy Medication Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Africa Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 107. Africa Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 108. Africa Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 109. Africa Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 110. Africa Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 111. Africa Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 112. Africa Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 113. Global Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 117. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 118. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 119. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 120. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. ASEAN Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 122. GCC Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. GCC Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 124. GCC Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 125. GCC Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 126. GCC Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 127. GCC Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 128. GCC Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 129. GCC Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 130. European Union Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. European Union Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. European Union Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 133. European Union Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 134. European Union Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 135. European Union Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 136. European Union Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. European Union Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 138. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 140. BRICS Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 141. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 142. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 143. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 144. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. BRICS Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 146. G7 Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 147. G7 Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. G7 Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 149. G7 Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 150. G7 Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 151. G7 Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 152. G7 Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 153. G7 Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 154. NATO Benign Prostatic Hypertrophy Medication Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. NATO Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. NATO Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 157. NATO Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 158. NATO Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 159. NATO Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 160. NATO Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 161. NATO Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 162. Global Benign Prostatic Hypertrophy Medication Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. United States Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 164. United States Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 165. United States Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 166. United States Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 167. United States Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 168. United States Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 169. United States Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 170. United States Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 171. Canada Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 172. Canada Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 173. Canada Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 174. Canada Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 175. Canada Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 176. Canada Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 177. Canada Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 178. Canada Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 179. Mexico Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 180. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 181. Mexico Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 182. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 183. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 184. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 185. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 186. Mexico Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 187. Brazil Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 188. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 189. Brazil Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 190. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 191. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 192. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 193. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Brazil Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 195. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 196. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 197. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 198. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 199. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 200. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 201. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. United Kingdom Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 203. Germany Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 204. Germany Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 205. Germany Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 206. Germany Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 207. Germany Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 208. Germany Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 209. Germany Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Germany Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 211. France Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 212. France Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 213. France Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 214. France Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 215. France Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 216. France Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 217. France Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 218. France Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 219. Russia Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 220. Russia Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 221. Russia Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 222. Russia Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 223. Russia Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 224. Russia Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 225. Russia Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. Russia Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 227. Italy Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 228. Italy Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 229. Italy Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 230. Italy Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 231. Italy Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 232. Italy Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 233. Italy Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 234. Italy Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 235. Spain Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 236. Spain Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 237. Spain Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 238. Spain Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 239. Spain Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 240. Spain Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 241. Spain Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 242. Spain Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 243. China Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 244. China Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 245. China Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 246. China Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 247. China Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 248. China Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 249. China Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 250. China Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 251. India Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 252. India Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 253. India Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 254. India Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 255. India Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 256. India Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 257. India Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. India Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 259. Japan Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 260. Japan Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 261. Japan Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 262. Japan Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 263. Japan Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 264. Japan Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 265. Japan Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Japan Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 267. Australia Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 268. Australia Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 269. Australia Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 270. Australia Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 271. Australia Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 272. Australia Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 273. Australia Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. Australia Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 275. South Korea Benign Prostatic Hypertrophy Medication Market Size, 2017-2032 (USD Million)
TABLE 276. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 277. South Korea Benign Prostatic Hypertrophy Medication Market Size, by 5-Alpha Reductase Inhibitors, 2017-2032 (USD Million)
TABLE 278. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Alpha Blockers, 2017-2032 (USD Million)
TABLE 279. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Combination Therapies, 2017-2032 (USD Million)
TABLE 280. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Drug Type, 2017-2032 (USD Million)
TABLE 281. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 282. South Korea Benign Prostatic Hypertrophy Medication Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 283. Global Benign Prostatic Hypertrophy Medication Market Share, by Key Player, 2025
TABLE 284. Global Benign Prostatic Hypertrophy Medication Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Ferring Pharmaceuticals
  • GlaxoSmithKline plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032 - Product Image

Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Drugs for Benign Prostatic hypertrophy Market Report 2026 - Product Image

Drugs for Benign Prostatic hypertrophy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Benign Prostatic Hyperplasia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2026 - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 210 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.